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Abstract
Background: Melanoma patients frequently develop brain metastases. The most widely used score to predict
survival is the molGPA based on a mixed treatment of stereotactic radiotherapy (SRT) and whole brain radiotherapy
(WBRT). In addition, systemic therapy was not considered. We therefore aimed to evaluate the performance of the
molGPA score in patients homogeneously treated with SRT and concurrent targeted therapy or immunotherapy
(TT/IT).
Methods: This retrospective analysis is based on an international multicenter database (TOaSTT) of melanoma
patients treated with TT/IT and concurrent (≤30 days) SRT for brain metastases between May 2011 and May 2018.
Overall survival (OS) was studied using Kaplan-Meier survival curves and log-rank testing. Uni- and multivariate
analysis was performed to analyze prognostic factors for OS.
Results: One hundred ten patients were analyzed. 61, 31 and 8% were treated with IT, TT and with a simultaneous
combination, respectively. A median of two brain metastases were treated per patient. After a median follow-up of 8
months, median OS was 8.4 months (0–40months). The molGPA score was not associated with OS. Instead, cumulative
brain metastases volume, timing of metastases (syn- vs. metachronous) and systemic therapy with concurrent IT vs. TT
influenced OS significantly. Based on these parameters, the VTS score (volume-timing-systemic therapy) was established
that stratified patients into three groups with a median OS of 5.1, 18.9 and 34.5months, respectively (p = 0.001 and 0.03).
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Conclusion: The molGPA score was not useful for this cohort of melanoma patients undergoing local therapy for brain
metastases taking into account systemic TT/IT. For these patients, we propose a prognostic VTS score, which needs to be
validated prospectively.
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Background
About 40–60% of melanoma patients will develop brain
metastases during the course of their disease, which con-
tributes to a worse prognosis and quality of life [1]. Me-
dian overall survival (OS) from presentation of brain
metastases to death used to be only 3 months [2]. Recent
developments in the fields of targeted- and immunother-
apy (TT/IT), as well as the now widespread use of
stereotactic radiosurgery (single fraction, SRS) and
stereotactic radiotherapy (fractionated stereotactic radio-
therapy, SRT) have significantly improved survival [3]. In
the following, the term SRT will be used for both, single-
and multi-fraction stereotactic radiotherapy. Despite re-
sponse rates of melanoma brain metastases of up to 40–
60% to IT and TT, presence of brain metastases remains
a limiting factor for survival [4–8], indicating that IT/TT
as monotherapy is often not sufficient. SRT is effective
in controlling brain metastases, with the advantage of
preserving cognitive function compared to whole brain
radiotherapy (WBRT) [9–11]. For a limited number of
up to four brain metastases, SRT without WBRT is now
the preferred treatment option [12]. However, evidence
is emerging that not number, but the volume of brain
metastases determines whether patients should receive
SRT [10]. In the rapidly changing setting of treatment
opportunities for melanoma patients it remains unclear,
which patients benefit most from local treatment and
there is a need for a reliable prognostic score to tailor
treatment.
Several scores have been developed aiming to predict
survival in patients with brain metastases [13–15]. How-
ever, caution is required as these scores have not been
established or validated in patients treated with com-
bined SRT and TT/IT. In 2010, Sperduto et al. presented
a refined version of the Graded Prognostic Assessment
(GPA) focusing on melanoma patients (ds-GPA) [16].
Karnofsky performance status (KPS) and number of
brain metastases were identified as prognostic factors for
OS. Recently, the group updated the score in the light of
new molecular markers, named molGPA score [17]. In
addition to the above-mentioned factors, age, BRAF-
mutational status and presence or absence of extracra-
nial metastases were added as prognostic markers. The
score is four-tired as its predecessor and reflects the suc-
cess of the advances in treatment by markedly prolonged
median OS as compared to the ds-GPA [17]. However,
radiation treatment consisted of a multitude of different
treatment regimens including surgery + SRT/WBRT,
WBRT +/− SRT, or SRT alone. Furthermore, the score
did not take into account whether and what systemic
treatment these patients received as background to local
treatment. In the only study to date that validated the
molGPA score, 70% of patients received WBRT and con-
current systemic therapy was likewise not recorded [18].
Other available scores have been shown to underestimate
OS as these were all developed before widespread imple-
mentation of TT/IT [19]. Two studies have aimed to val-
idate prognostic scores in TT/IT-treated patient cohorts
that received concomitant SRT to date, albeit omitting the
most widely used molGPA score [20, 21]. Hence, this
study aims to validate the molGPA score in a cohort of
patients homogeneously treated with SRT and concurrent
TT/IT to depict patterns of care of modern melanoma
treatment.
Methods
A retrospective international multicenter registry study
(TOaSTT) was established to collect data on patients re-
ceiving SRT (delivery of up to 10 high-dose stereotactic
radiation fractions) with concurrent targeted- or im-
munotherapy. Ethics approval was obtained by the lead
ethics committee in Zurich (BASEC-Nr. 2016–01807)
and from all participating centers at their local ethics
committees. For sub- analysis of melanoma patients with
brain metastases, patients meeting the following criteria
were included: ≥18 years of age, histopathologically con-
firmed diagnosis of melanoma with synchronous or
metachronous (> 6 months after first diagnosis) brain
metastases, patients receiving SRT of any number of
cerebral metastasis and concurrent treatment with any
type of the following targeted drugs: antibodies and tyro-
sine kinase inhibitors (targeted therapies, TT) and
immune-checkpoint inhibitors (immunotherapy, IT).
“Concurrent” was defined as application of the respect-
ive drug within 30 days prior or after SRT. SRT was de-
fined as delivery of single or fractionated large dose
irradiation fractions ranging from 1 × 18 Gy to 1 × 21 Gy
for SRS or from 5 × 5 Gy to 6 × 5 Gy for SRT; Patients
treated with linac-based SRT, robotic-SRT (Cyberknife)
as well as Gammaknife were eligible. Patients receiving
concurrent whole brain radiotherapy (WBRT) were ex-
cluded as well as melanoma patients in the database that
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only received stereotactic radiotherapy extracranially.
Patients were included irrespective of prior treatment
regimens.
Overall survival (OS) was defined as time of start of
SRT to time of death, living patients were censored at
the date of last follow-up. In the case of multiple cere-
bral stereotactic irradiations, OS was calculated from
start of last stereotactic treatment.
The score by Sperduto et al. was applied and groups
were formed as described in the original publication
awarding points for age, KPS, extracranial metastases,
BRAF-status and number of brain metastases [17]. After
performing uni- and multivariate analyses for patient-,
tumor- and treatment factors associated with OS, we
established a new prognostic score using factors of stat-
istical significance.
Descriptive statistical analysis was performed with
SPSS v25.0 statistic software package (IBM Corp.,
Armonk, NY, USA). The Kaplan-Meier method followed
by log-rank analysis for comparison of subgroups was
used to evaluate OS. Univariate and multivariate Cox re-
gression analysis (Enter method) was performed to iden-
tify independent variables for OS. Chi-square test was
used to compare differences between two independent
groups. A p-value of less than 0.05 was deemed statisti-
cally significant.
Results
Patient and treatment characteristics
Patient and treatment characteristics are shown in
Table 1.
One hundred ten patients were eligible for sub-analysis
form the TOaSTT database. Median age at time of radi-
ation was 59.4 years (25–82 years). The large majority of
patients had a good performance status of ECOG 0–1
(93.6%). The median number of SRT-treated brain metas-
tases was 2 (1–30). Forty-seven patients had a single me-
tastasis, 53 had 2–4 metastases and 10 patients had > 4
brain metastases. The large majority of patients had extra-
cranial metastases at time of cerebral SRT (83 patients;
75.5%), while only 27 patients (24.5%) suffered from exclu-
sively cerebral disease. The median cumulative brain me-
tastases volume was 1.5 cc ranging from 0.05–24.5 cc.
Fifty-seven (48.2%) patients harbored BRAF-mutations,
53 (51.8%) did not or it was unknown.
No Patients were treatment-naïve: 92% had received
surgery (mostly for the primary tumor), 19% had received
conventional immunotherapy (IL-2 or interferone), 23.6%
had received conventionally fractionated radiotherapy,
2.7% had been treated with conventional chemotherapy,
38% had received previous SRT to the brain. In those
cases, the last SRT was included in this analysis.
The majority of patients received concurrent IT alone
(60.9%). Of those, 25.5% of patients received
pembrolizumab, 16.3% ipilimumab, 12.7% nivolumab,
the remaining 8% were treated with combinations of IT.
Of all patients, 30.9% were treated with targeted therapy
alone: Dabrafenib/trametinib was administered in 9% of
cases, 8% received vemurafenib. The remaining nine pa-
tients received BRAF and/or MEK inhibitors (dabrafenib,
binimetinib, trametinib, vemurafenib/cobimetinib, ver-
murafenib/osimertinib, encorafenib/binimetinib). Nine
patients were treated with a combination of IT and TT.
TT/IT was paused during SRT in 47% of patients. It was
paused a median of 5 days (1–28 days) before SRT and
restarted a median of 7 days (1–25 days) after SRS/SRT.
Total median pause length was 14 days (1–29 days). In
49% of patients, TT/IT was not paused during SRT, data
was missing for four patients. Patients treated with SRS
Table 1 Patient and treatment characteristics










Number of brain metastases median: 2 (1–30)
1 47 (42.7)
2–4 53 (48.1)
> 4 10 (9.0)
BRAF status
positive 57 (48.2)




volume of brain metastases
≥ 1.5 cc 55 (50.0) 1.5–24.54 cc








Abbreviations: SRS Stereotactic radiosurgery, SRT Stereotactic radiotherapy, IT
Immunotherapy, TT Targeted therapy
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received a median of 20 Gy in one fraction (n = 95; range
18-21Gy). Patients treated with SRT received 25-30Gy
total dose (n = 15; regimens varied between 5x5Gy,
6x5Gy or 5x6Gy). Patients were treated with c-arm-
based SRT with linear accelerators, robotic-based SRT
(CyberKnife, Accuray, Sunnyvale, USA) as well as
Gamma Knife (Elekta, Stockholm, Sweden). Median
follow-up was 8 months (0–39 months) and median OS
was 8.4 months (0–40months).
Survival analysis by molGPA score factors
The prognostic factors of the molGPA score were ana-
lyzed. These are age, performance status, presence of ex-
tracranial disease, BRAF-status, and the number of brain
metastases: OS between patients older or younger than
70 years did not differ (p = 0.98). Performance status did
influence survival on univariate, but not on multivariate
analysis (Table 2).
Patients with extracranial disease had a significantly worse
OS compared to patients without extracranial disease in uni-
variate analysis (p= 0.02) but not on multivariate analysis.
Patients harboring BRAF-mutations had a worse OS com-
pared to patients with an unknown or no BRAF-mutation
(p= 0.02). Median OS in the patient group with BRAF-
mutations was 5.4months whereas median OS for BRAF-
wild type patients (or with an unknown BRAF-status) was
10.7months (p= 0.001). Importantly, the ECOG perform-
ance status did not differ between the BRAF positive and
negative/unknown groups (p= 0.5). The number of SRT-
treated brain metastases did not influence OS (p = 0.29)
(1 vs. 2–4 metastases p = 0.12, 1 vs. > 4 metastases
p = 0.07; 2–4 vs > 4 metastases p = 0.68).
Univariate analysis was additionally performed for cumula-
tive brain metastases volume, timing of metastases (syn- vs.
metachronous), type of systemic therapy (IT vs. no IT) and
whether other metastases were controlled at time of SRT. In
contrast to the number of brain metastases, OS was signifi-
cantly associated with the cumulative brain metastases vol-
ume: patients with a cumulative brain metastases volume of
< 1.5 cc had a median OS of 15.5months, while the median
OS for ≥1.5 cc brain metastases volume was 6.1months (p=
0.02). On multivariate analysis, only cumulative brain metas-
tases volume, timing of metastases and type of systemic
treatment remained statistically significant (Table 2).
Application of the molGPA score and the VTS score
The molGPA score was applied to the cohort as described
by the authors to estimate survival. Median OS was 4.8, 8.8,
15.0 and 15.5months for the four groups with 0–1 points,
1.5–2 points, 2.5–3 point and 3.5–4 points, respectively. The
score did not differentiate between the four groups well
(log-rank across strata p = 0.1, Fig. 1a).
Based on the findings of the analysis, a different score,
named the VTS score was established, where cumulative
brain metastasis volume, timing of metastases and type
of systemic treatment were included as described above
(Tables 3 and 4).
The groups were formed as described in a three-tiered
manner. The VTS score was significantly associated with
OS (p < 0.0001, Fig. 1b) with a median OS in the three
groups of 5.1, 18.9 and 34.5 months, respectively.
When analyzing the sensitivity and specificity of the
two scores to predict survival of patients at 6 months,
the molGPA score did not show the capacity to predict
survival, whereas the VTS score improved the prediction
significantly. Hence, in a cohort of patients treated
homogenously with concurrent IT/TT and SRT, other
factors than those informing the molGPA score may be
of improved prognostic power (Fig. 2).
Discussion
To our knowledge, this is the first study attempting to val-
idate the molGPA score in a cohort of melanoma patients
with brain metastases, which was homogeneously treated
with concurrent SRT and targeted- or immunotherapy. As
these treatment combinations are rapidly implemented in
routine practice, it is crucial to validate this score or de-
velop more appropriate ones for this patient cohort. Using
the measures proposed by Sperduto and colleagues [17], we
were unable to validate the molGPA score. However, when
using the factors cumulative brain metastasis volume, tim-
ing of brain metastases development and type of systemic
treatment, survival was stratified in a statistically significant
manner. On analysis using the receiver-operating-curve for
the binary endpoint of 6-months-OS, the VTS score out-
performed the molGPA with an AUC of 0.74 vs. 0.53.
Concurrent systemic treatment and SRT
Retrospective studies have investigated concurrent treat-
ment of TT/IT and SRT in melanoma patients to date. Me-
dian OS was 7.5months for concomitant CTLA-4-
inhibitors, 17.8months for concomitant BRAF-inhibitors
and 20.4months for concomitant anti-PD-1 treatment in a
retrospective study of 108 melanoma patients receiving
SRT for brain metastases (notably, 40% of patients received
an additional WBRT) [22]. Gaudy-Marqueste et al. treated
all brain metastases upfronct with SRT followed by IT/TT.
The cohort of 179 patients showed a median OS of 10.9
months [3]. Recently, 80 patients treated with concurrent
ipilimumab or nivolumab and SRT to melanoma brain me-
tastases were evaluated retrospectively for progression-free
survival, OS and toxicity profile [23]. The OS times in the
present study are in line with these studies.
In our cohort, treatment with immunotherapy was a factor
positively associated with OS compared to concomitant use
of targeted therapy. Only two prospective phase I studies are
available at the moment evaluating the safety of concurrent
SRT and nivolumab and ipilimumab, respectively [24, 25]. It
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has been hypothesized that SRT has the propensity to syner-
gize with IT through five factors: 1) inducing immunogenic
cell death by generating antigens 2) promoting antigen pres-
entation on MHC I molecules enhancing the tumor cell kill-
ing through CD8 cytotoxic T-cells, 3) increasing blood-
brain-barrier-permeability, 4) inducing chemokines that help
overcome T-cell exclusion from the metastases and 5)
through the rare abscopal effect [26–28]. A retrospective
analysis of 395 patients with advanced melanoma in
Switzerland likewise showed an improved median OS for pa-
tients receiving IT compared to TT (16.7months vs. 11.2
months) [29]. However, only few prospectively collected
datasets have retrospectively investigated this potential syn-
ergy to date [24, 30, 31].
It currently remains unclear whether BRAF-mutated
patients should receive TT or IT as first line therapy. It
has been suggested that the type of BRAF-mutation
(V600E vs. V600K) influences treatment response: The
V600E mutation is more prone to responding to TT,
while V600K-mutated tumors typically employ a higher
tumor mutational burden and respond better to IT [32].
In this study, DNA-expression profiles to detect these
differences were not available but should be investigated
in the future to tailor treatment. There are multiple
Table 2 Uni- and multivariate analysis (Cox regression, Enter method)
n Univariate P-value Multivariate
Enter
P-value
HR (death) (95% CI) HR (death) (95% CI)
Agea
< 70 82 0.99 (0.56–1.76) 0.98 0.76 (0.38–1.5) 0.43
≥ 70 27
ECOGa
0 77 0.46 (0.27–0.77) 0.002 0.68 (0.39–1.19) 0.18
> 0 33
BRAFa
Mutated 56 0.56 (0.34–0.93) 0.02 0.58 (0.32–1.05) 0.07
Wild type/unknown 53
Number of brain metastasesa




present 82 0.42 (0.56–1.76) 0.02 1.35 (0.37–4.98) 0.65
absent 27
Brain metastases volume
< 1.5 cc 54 0.56 (0.34–0.94) 0.03 0.54 (0.29–0.96) 0.04
≥ 1.5 cc 55
Timing
Synchronous 25 1.84 (1.05–3.24) 0.03 2.43 (1.24–4.75) 0.01
metachronous 84
Systemic therapy




No 38 0.25 (0.01–1.97) 0.001 0.15 (0.01–12.18) 0.78
yes 34
mixed 17
no other metastases 19
Abbreviations: HR Hazard ratio, CI Confidence interval; a = factors in the original molGPA score
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trials investigating the IT-TT combination treatment for
BRAF-mutated melanoma patients showing overall re-
sponse rates of up to 100%, albeit with 22% of patients
discontinuing treatment due to toxicity (COMBI-I trial).
BRAF-mutation associated with worse OS
It was surprising that the BRAF-mutated patients in our
cohort had a significantly worse OS than BRAF-wildtype
patients. This might be explained by the effects of IT:
Fig. 1 Kaplan-Meier curves comparing (a) the molGPA score with (b) the VTS score including cumulative brain metastases volume, timing of
metastases, cumulative brain metastases volume and concomitant systemic treatment
Table 3 Survival of patients grouped by the VTS score
VTS score n = 110 median OS (months) logrank pairwise
0–1 46 5.1 vs. 1.5: 0.001
vs. 2: 0.0001
1.5 36 18.9 vs. 2: 0.03
2 28 34.5
Abbreviations: VTS Volume-timing-systemic therapy, OS Overall survival
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patients might have received IT at an earlier time point
which then achieved improved OS [3]. Additionally, it has
been acknowledged, that the timing of IT/TT and SRT is
crucial [12, 33]. Recently, the immunomodulatory effects
of SRT has been discussed in the literature leading to syn-
ergistic effects of the combined treatment as discussed
above that might also be reflected in our finding [28, 34].
In the original molGPA study, BRAF-status was divided
into three groups: positive, negative and unknown;
whereby the unknown status (29% of patients) yielded the
highest hazard ratio (1.94 vs 1.3 for negative and 1.0 for
positive); nevertheless, negative and unknown were
awarded 0 points in the score, raising doubts about the
strength of prognostic value of this factor. In contrast, our
data was very complete regarding BRAF-mutational status:
the BRAF-status was unknown for only 7 patients.
The cumulative brain metastases volume factor
The first prognostic score index for radiosurgery (SIR) for
brain metastases treated with SRT (including 10 melanoma
patients; 15.3%) already included a volume factor stratifying
by the largest irradiated lesion in three groups (< 5 cc, 5-13
cc and > 13 cc) [35]. SIR also considered the number of
brain metastases. By using the cumulative brain metastases
volume, parts of both factors are combined. A more recent
evaluation of multiple prognostic scores (omitting the most
recent molGPA score) by Badakhshi et al. had shown the
cumulative brain metastases volume to be of importance.
However, while yielding the highest level of statistical
significance on univariate analysis, cumulative brain metas-
tases volume did not remain a statistically significant prog-
nostic factor on multivariate analysis. The authors likewise
stratified patients by smaller or larger than median cumula-
tive brain metastases volume, which was similar to the me-
dian cumulative brain metastases volume in this study
(2.47 cc) [20]. In their cohort of 80 patients, only 8.8% of
patients received concurrent TT/IT. An evaluation of prog-
nostic scores in 66 melanoma patients treated with SRT-
only for brain metastases further supports the hypothesis
that cumulative brain metastases volume contains more
prognostic power compared to the mere number: on multi-
variate analysis, age > 60 years, performance status ≤80%,
and notably, cumulative brain metastases volume > 2 cc was
associated with worse OS, while number of brain metasta-
ses was not [36].
Of note, the authors of the molGPA score had investi-
gated volume of brain metastases, although merely for
SRS-only treated patients in their cohort (56%). It is not
reported, whether this was the cumulative volume. Add-
itionally, the brain metastases volume factor was applied
to the entire cohort, albeit 25% of patients received
WBRT, which could explain why this factor was not sta-
tistically significant for survival of the entire cohort [17].
Limitations
Limitations of this study include its retrospective charac-
ter, the small number of patients compared to the ori-
ginal molGPA publication, and the utilization of the
Table 4 Awarded points for VTS score
0 points 0.5 points 1 point
Cumulative brain metastases volume > 1.5 cc < 1.5 cc
Timing synchronous metachronous
Systemic treatment targeted therapy immunotherapy
Fig. 2 Receiver operating curves (ROC, red line = diagonal reference line) for (a) the molGPA score and (b) the VTS score for the binary endpoint
of 6-months-OS with 60 patients reaching this endpoint. The AUC was improved with the VTS score
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ECOG score rather than the smaller scaled KPS. In the
future, the newly developed VTS score needs to be ex-
ternally validated. Notably, only 3.6% of patients received
concurrent ipilimumab/nivolumab as systemic treatment
with SRT, which is the standard of care treatment as of
today [5, 6], which may be due to the recruitment time
between 2011 and 2018. Combinations of BRAFi and
MEKi were applied in 16.3% of cases, a standard TT-
treatment for BRAF-mutated cutaneous melanoma ac-
cording to ESMO guidelines [37]. FFig.
Conclusion
In conclusion, this study shows for the first time, that
the molGPA score has to be used with caution for the
rapidly growing cohort of melanoma patients treated
with SRT concurrent with immuno- or targeted therap-
ies for brain metastases. Factors such as cumulative
brain metastasis volume, timing of metastases and type
of systemic treatment should be taken into account in
this cohort. In the future, timing of TT/IT and SRT
should be investigated further and the VTS score should
be validated to enrich the clinical decision-making tool
enabling physicians to make the best decisions regarding
treatment of brain metastases for their melanoma
patients.
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